Les patients canadiens devraient-ils fonder leurs espoirs sur l’aducanumab pour la maladie d’Alzheimer?

Watt JA, Marple R, Hemmelgarn B, Straus SE.

DOI: 10.1503/cmaj.211134-f
Published: 2021-11-01
Container: CMAJ
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1503/cmaj.211134-f,
  title = {Les patients canadiens devraient-ils fonder leurs espoirs sur l’aducanumab pour la maladie d’Alzheimer?},
  author = {Watt JA and  Marple R and  Hemmelgarn B and  Straus SE.},
  year = {2021},
  journal = {CMAJ},
  doi = {10.1503/cmaj.211134-f},
  url = {https://doi.org/10.1503/cmaj.211134-f}
}

RIS

TY  - JOUR
TI  - Les patients canadiens devraient-ils fonder leurs espoirs sur l’aducanumab pour la maladie d’Alzheimer?
AU  - Watt JA
AU  -  Marple R
AU  -  Hemmelgarn B
AU  -  Straus SE.
PY  - 2021
JO  - CMAJ
DO  - 10.1503/cmaj.211134-f
UR  - https://doi.org/10.1503/cmaj.211134-f
ER  -

APA

JA, W., R, M., B, H., & SE., S. (2021). Les patients canadiens devraient-ils fonder leurs espoirs sur l’aducanumab pour la maladie d’Alzheimer?. CMAJ. https://doi.org/10.1503/cmaj.211134-f

Source records

europe-pmc · retrieved 2026-09-26T15:54:43.601Z